Alnylam Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript
Good morning. I'm Mani Foroohar, managing director and senior analyst, genetic medicines here at SVB Leerink. And I am very fortunate to be joined by Yvonne Greenstreet, COO of Alnylam Pharmaceuticals.
Yvonne, do you want to start with a couple of quick slides and overview?
Yes, sounds like a great idea. First of all, good morning, everybody. I'm absolutely delighted to be here. Glad we can still travel to conferences for now anyway. Obviously, there's the usual forward-looking statements that you can read on the screen.
We're really excited at Alnylam to be the pioneers in translating Nobel Prize-winning science into a product engine for sustainable innovation. And I think one of the remarkable things about our approach is the reproducible and modular approach that we've developed. And focusing on genetically validated targets has allowed us to deliver success
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
